Santhera Pharmaceuticals Holding AG
🇬🇧XLON.0QN1United KingdomNot reported
Price£15.36+0.26 (+1.72%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 4
- Medium: 0
- Low: 0
Financial leverage: a sudden drop below its trailing quarter average
Gross profit margin: a sudden drop below its trailing quarter average
Return on equity: a sudden spike above its trailing quarter average
Working capital turnover: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- United Kingdom
Identity
- Exchange
- London Stock Exchange . XLON
- Type
- Stock
- ISIN
- CH1276028821
- CUSIP
- Not reported
Company
- Employees
- 78
- Headquarters
- Pratteln, United Kingdom
- Website
- https://www.santhera.com
Market
- Shares outstanding
- 6.4M
- Market cap
- £177.63M
Highlights
- Market cap
- £177.63M
- EPS LTM
- CHF 8.32
- P/E LTM
- Not reported
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CHF 170.33M+2,099.75%up year on year
- Net income
- CHF 94.28M+197.17%up year on year
- Gross margin
- 94.06%+339.15%up year on year
- Free cash flow
- CHF 70.78M+231.44%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Santhera Pharmaceuticals Holding AG is listed on London Stock Exchange (United Kingdom) under the ticker 0QN1. Its market capitalisation is £177.63M, from 6.4M shares outstanding, as of . Across the 248 trading sessions to the shares traded between £9.50 and £18.72, and the last close of £15.36 sits 64% of the way up that range. The company is headquartered in Pratteln, United Kingdom, and employs about 78 people. This is the London Stock Exchange listing of Santhera Pharmaceuticals Holding AG; its primary listing is SANN on SIX Swiss Exchange.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.